Schizophrenia: A purinergic hypothesis

Medical Hypotheses

Volumn 54, Issue 2, 2000, Pages 157-166

  Lara, D R ^a   Souza, D O ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; PURINE;

ARTICLE; DOPAMINERGIC SYSTEM; EPILEPSY; INFLAMMATION; MODEL; NEUROTRANSMISSION; PAIN; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA;

EID: 0034018798     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1999.0003     Document Type: Article

References (113)

1. Horrobin D. F. Schizophrenia as a membrane lipid disorder which is expressed throughout the body. Prostaglandins Leukot Essent Fatty Heads. 55:1996;3-7.
2. Horrobin D. F. Schizophrenia: the illness that made us human. Med Hypotheses. 50:1998;269-288.
3. Neary J. T., Rathbone M. P., Cattabeni F., Abbracchio M. P., Burnstock G. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci. 19:1996;13-18.
4. Ralevic V., Burnstock G. Receptors for Purines and Pyrimidines. Pharmacol Rev. 50:1998;413-492.
5. Brundege J. M., Dunwiddie T. V. Role of adenosine as a modulator of synaptic activity in the central nervous system. Adv Pharmacol. 39:1997;353-391.
6. Nehlig A., Daval J. L., Debru G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Rev. 17:1992;139-170.
7. Seeman P., Tallerico T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 3:1998;123-134.
8. Lucas P. B., Pickar D., Kelsoe J., Rapaport M., Pato C., Hommer D. Effects of the acute administration of caffeine in patients with schizophrenia. Biol Psychiatry. 28:1990;35-40.
9. Kafka S. H., Corbett R. Selective adenosine A2a receptor/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol. 295:1996;147-154.
10. Rimondini R., Ferre S., Ogren S. O., Fuxe K. Adenosine A2A agonists: a potential new type of atypical antipsychotic. Neuropsychopharmacol. 17:1997;82-91.
11. Rimondini R., Ferré S., Giménez-Llort L., Ögren S. O., Fuxe K. Differential effects of selective adenosine A1 and A2a receptor agonists on dopamine receptor agonist induced behavioral responses in rats. Eur J Pharmacol. 347:1998;153-158.
12. Wardas J., Pinna A., Cozzolino A., Morelli M. Involvement of adenosine A2A receptors in the c-Fos expression induced by clozapine and haloperidol. Eur Neuropsychopharm. 8:1998;S213-214.
13. Knable M. B., Kleinman J. E., Weinberger D. R. Neurobiology of schizophrenia. The American Psychiatric Press Textbook of Psychopharmacology, 2nd edn. 1998;American Psychiatric Press, Washington, DC. p. 589-607.
14. Ferré S. Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology. 133:1997;107-120.
15. Zetterström T., Fillenz M. Adenosine agonists can both inhibit and enhance in vivo striatal dopamine release. Eur J Pharmacol. 180:1990;137-143.
16. Hietala J., Syvalahti E., Vuorio K. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet. 346:1995;1130-1131.
17. Dao-Castellana M. H., Paillere-Martinot M. L., Hantraye P. Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophrenia Res. 23:1997;167-174.
18. Lindström L. H., Gefvert O., Hagberg G. Increased synthesis of dopamine in prefrontal cortex and striatum in drug-naive schizophrenic patients studied by use of C11-labelled I-DOPA and PET. Schizophr Res. 29:1998;93-94.
19. 11C]raclopride. Arch Gen Psychiatry. 47:1990;213-219.
20. Ferré S., Euler Gv., Johansson B., Fredholm B., Fuxe K. Stimulation of high affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes. Proc Natl Acad Sci USA. 88:1991;7238-7241.
21. Müller-Spahn F., Modell S., Ackenheil M., Brachner A., Kurtz G. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients. J Psychiat Res. 32:1998;265-271.
22. Olney J. W., Farber N. B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 52:1995;998-1007.
23. Tamminga C. A. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol. 12:1998;21-36.
24. Hoehn K., White T. D. Role of excitatory aminoacid receptors in K+- and glutamate-evoked release of endogenous adenosine from rat cortical slices. J Neurochem. 54:1990;256-265.
25. 3H]norepinephrine from rat cortical slices. J Pharmacol Exp Ther. 255:1990;174-181.
26. Craig C. G., White T. D. NMDA- and non-NMDA-evoked adenosine release from rat cortical slices: distinct purinergic sources and mechanisms of release. J Neurochem. 60:1993;1073-1080.
27. Delaney S. M., Shepel P. N., Geiger J. D. Levels of endogenous adenosine in rat striatum. I. Regulation by ionotropic glutamate receptors, nitric oxide and free radicals. J Pharmacol Exp Ther. 285:1998;561-567.
28. Browne R. G., Welch W. M. Stereoselective antagonism of phencyclidine's discriminative properties by adenosine receptor agonists. Science. 217:1982;1157-1159.
29. Popoli P., Caporali M. G., Scotti de Carolis A. Evidence of the involvement of D1 dopamine receptors in PCP-induced stereotypy and ataxia in rabbits. Pharmacol Res. 22:1990;197-205.
30. Popoli P., Reggio R., Pèzzola A. Adenosine A1 and A2 receptor agonists significantly prevent the eletroencephalographic effects induced by MK-801 in rats. Eur J Pharmacol. 333:1997;143-146.
31. Fraser C. M., Fisher A., Cooke M. J., Thompson I. D., Stone T. W. Purine modulation of dizocilpine effects on spontaneous alternation. Psychopharmacology. 130:1997;334-342.
32. Beardsley P. M., Balster R. L. Evaluation of antagonists of the discriminative stimulus and response rate effects of phencyclidine. J Pharmacol Exp Ther. 244:1988;34-40.
33. Feinberg I., Campbell I. G. Haloperidol potentiates the EEG slowing of MK-801 despite blocking its motor effects: implications for the PCP model of schizophrenia. Neuroreport. 9:1998;2189-2193.
34. Goff D. C., Wine L. Glutamate in schizophrenia: clinical and research implications. Schizophrenia Res. 27:1997;157-168.
35. Evins A. E., Amico E. T., Shih V., Goff D. C. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm. 104:1997;761-766.
36. Maitre M., Ciesieslki L., Lehmann A., Reempl E., Mandel P. Protective effects of adenosine and nicotinamide against audiogenic seizures. Biochem Pharmacol. 23:1974;2807-2816.
37. Dunwiddie T. V., Worth T. Sedative and anticonvulsant effects of adenosine analogues in mouse and rat. J Pharmacol Exp Ther. 220:1982;70-76.
38. Dragunow M. Purinergic mechanisms in epilepsy. Progr Neurobiol. 31:1988;85-108.
39. Zhang G., Franklin P. H., Murray T. F. Manipulation of endogenous adenosine in the rat prepiriform cortex modulates seizure susceptibility. J Pharmacol Exp Ther. 264:1993;1415-1424.
40. During M. J., Spencer D. D. Adenosine: a potential mediator of seizure arrest and postictal refractoriness. Ann Neurol. 32:1992;618-624.
41. Pagonopoulou O., Angelatou F. Time development and regional distribution of [3H]nitrobenzylthioinosine adenosine uptake site binding in the mouse brain after acute Pentylenetetrazol-induced seizures. J Neurosci Res. 53:1998;433-442.
42. Chu N. S. Caffeine and aminophylline-induced seizures. Epilepsia. 22:1981;85-94.
43. Glass M., Faull R. L. M., Bullock J. Y. Loss of A1 adenosine receptors in human temporal lobe epilepsy. Brain Res. 710:1996;56-68.
44. Hyde T. M., Weinberger D. R. Seizures and schizophrenia. Schizophr Bull. 23:1997;611-622.
45. Meltzer H. Y. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull. 18:1992;515-542.
46. Popoli P., Benedetti M., Scotti de Carolis A. Anticonvulsant activity of carbamazepine and N6-L-phenylisopropyladenosine in rabbits. Relationship to adenosine receptors in the central nervous system. Pharmacol Biochem Behav. 29:1988;533-539.
47. Suwalska A., Rybakowsky J. Potentiation of antidepressants with lithium and carbamazepine: factors associated with therapeutic efficacy. Eur Neuropsychopharm. 8:1998;S157-158.
48. Fink M., Sackeim H. A. Convulsive therapy in schizophrenia? Schizophr Bull. 22:1996;27-39.
49. Newman M., Zohar J., Kalian M., Belmaker R. H. The effects of chronic lithium and ECT on A1 and A2 adenosine receptor systems in rat brain. Brain Res. 291:1984;188-192.
50. Francis A., Fochtmann L. Reduced proconvulsant activity of caffeine in rats after a series of electroconvulsive seizures. Psychopharmacology. 119:1995;99-104.
51. Lippert S., Werman D. S. Schizophrenia and intercurrent physical illness: a critical review of the literature. Comprehens Psychiatr. 18:1997;11-22.
52. Madl J. E., Allen D. L. Hyperthermia depletes adenosine triphosphate and decreases glutamate uptake in rat hippocampal slices. Neuroscience. 69:1995;395-405.
53. Porkka-Heiskanen T., Strecker R. E., Thakkar M., Bjørkum A. A., Greene R. W., McCarley R. W. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 276:1997;1265-1268.
54. Benington J. H., Kodali S. K., Craig Heller H. Stimulation of A1 adenosine receptors mimics the eletroencephalographic effects of sleep deprivation. Brain Res. 692:1995;79-85.
55. Nishino S., Mognot E., Benson K. L., Zarcone V. P. Jr. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture. Psychiat Res. 78:1998;141-150.
56. Keshavan M. S., Reynolds C. F. III, Miewald J. M. Delta sleep deficits in schizophrenia. Arch Gen Psychiatry. 55:1998;443-448.
57. Häfner H., Heiden W., Behrens S. Causes and consequences of the gender difference in age at onset of schizophrenia. Schizophr Bull. 24:1998;99-113.
58. Cario-Toumaniantz C., Loirand G., Ferrier L., Pacaud P. Non-genomic inhibition of human P2X7 purinoceptor by 17beta-oestradiol. J Physiol. 508:1998;659-666.
59. Phillis J. W., O'Regan M. H. Effects of estradiol on cerebral cortical neurons and their responses to adenosine. Brain Res Bull. 20:1988;151-155.
60. Weinberger D. R. From neuropathology to neurodevelopment. Lancet. 346:1995;552-557.
61. Thome J., Foley P., Riederer P. Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses. J Neural Transm. 105:1998;85-100.
62. Zimmermann H. Extracellular purine metabolism. Drug Develop Res. 39:1996;337-352.
63. Zimmermann H. 5′-nucleotidase: molecular structure and functional aspects. Biochem J. 285:1992;345-365.
64. Schoen S., Graybiel A. M. 5′-nucleotidase: a new marker for striosomal organization in the rat caudoputamen. J Comp Neurol. 322:1993;566-576.
65. McCreadie R. G. The Nithsdale Schizophrenia Surveys. 16. Breast-feeding and schizophrenia: preliminary results and hypotheses. Br J Psychiatry. 170:1997;334-337.
66. Leach J. L., Baxter J. H., Molitor B. E., Ramstack M. B., Masor M. L. Total potentially available nucleosides of human milk by stage of lactation. Am J Clin Nutr. 61:1995;1224-1230.
67. Thorell L., Sjoberg L. B., Hernell O. Nucleotides in human milk: sources and metabolism by the newborn infant. Pediatr Res. 40:1996;845-852.
68. Sugawara M., Sato N., Nakano T., Idota T., Nakajima I. Profile of nucleotides and nucleosides of human milk. J Nutr Sci Vitaminol. 41:1995;409-418.
69. Nagai H., Ussui T., Akaishi K., Shigeyuki I. The effect of supplementation of nucleotides to commercial milk on the weight gain of premature and healthy infants. Ann Pediatr Jpn. 9:1963;169-175.
70. Carver J. D. Dietary nucleotides: cellular immune, intestinal and hepatic system effects. J Nutr. 124:1994;144S-148S.
71. Pickering L. K., Granoff D. M., Erickson J. R. Modulation of the immune system by human milk and infant formula containing nucleotides. Pediatrics. 101:1998;242-249.
72. DeLucchi C., Pita M. L., Faus M. J., Molina J. A., Uauy R., Gil A. Effects of dietary nucleotides on the fatty acid composition of erythrocyte membrane lipids in term infants. J Pediatr Gastroenterol Nutr. 6:1987;568-574.
73. Gil A., Pita M., Martinez A., Molina J. A., Sanchez Medina F. Effect of dietary nucleotides on the plasma fatty acids in at-term neonates. Hum Nutr Clin Nutr. 40:1986;185-195.
74. Gil A., Lozano E., De-Lucchi C., Maldonado J., Molina J. A., Pita M. Changes in the fatty acid profiles of plasma lipid fractions induced by dietary nucleotides in infants born at term. Eur J Clin Nutr. 42:1988;473-481.
75. Sato N., Murakami Y., Nakano T. Effects of dietary nucleotides on lipid metabolism and learning ability of rats. Biosci Biotechnol Biochem. 59:1995;1267-1271.
76. Olin S. C., Mednick A. S. Risk factors of psychosis: identifying vulnerable populations premorbidly. Schizophr Bull. 22:1996;223-240.
77. Ledent C., Vaugeois J. M., Schiffmann S. N. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature. 388:1997;674-678.
78. Jain N., Kemp N., Adeyemo O., Buchanan P., Stone T. W. Anxiolytic activity of adenosine receptor activation in mice. Br J Pharmacol. 116:1995;2127-2133.
79. Dumas T., Foster T. C. Late developmental changes in the ability of adenosine A1 receptors to regulate synaptic transmission in the hippocampus. Dev Brain Res. 105:1998;137-139.
80. Muller J., Rocha J. B., Battastini A. M., Sarkis J. J., Dias R. D. Postnatal development of ATPase-ADPase activities in synaptosomal fraction from cerebral cortex of rats. Neurochem Int. 23:1993;471-477.
81. Ward P. E., Sutherland J., Glen E. M., Glen A. I. Niacin skin flush in schizophrenia: a preliminary report. Schizophr Res. 29:1998;269-274.
82. Glen A. I. M., Glen E. M. T., Horrobin D. F. A red cell abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr Res. 12:1994;53-61.
83. Gattaz W. F., Hubner C. vK., Navalainen T. J. Increased serum phospholipase A2 activity in schizophrenia: a replication study. Biol Psychiatr. 28:1990;495-501.
84. Chen W. C., Chen C. C. ATP-induced arachidonic acid release in cultures astrocytes is mediated by Gi protein coupled P2Y1 and P2Y2 receptors. Glia. 22:1998;360-370.
85. Horrobin D. F., Ally A. I., Karmali R. A., Karmazyn M., Manku M. S., Morgan R. O. Prostaglandins and schizophrenia: further discussion of the evidence. Psychol Med. 8:1978;43-48.
86. Dworkin R. H. Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr Bull. 20:1994;235-248.
87. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol. 347:1998;1-11.
88. Bodin P., Burnstock G. Increased release of ATP from endothelial cells during acute inflammation. Inflamm Res. 47:1998;351-354.
89. Zimmermann H., Braun N., Kegel B., Heine P. New insights into the molecular structure and function of ecto-nucleotidases in the nervous system. Neurochem Int. 32:1998;421-425.
90. Brown S. Excess mortality of schizophrenia - a meta-analysis. Br J Psychiatr. 171:1997;502-508.
91. Chow S. C., Kass G. E., Orrenius S. Purines and their roles in apoptosis. Neuropharmacology. 36:1997;1149-1156.
92. Dzhandzhugazyan K. N., Kirkin A. F., Straten P., Zeuthen J. Ecto-ATP diphosphohydrolase/CD39 is overexpressed in differentiated human melanomas. FEBS Lett. 430:1998;227-230.
93. Nyhan W. L. The recognition of Lesch-Nyhan syndrome as an inborn error of purine metabolism. J Inher Metab Dis. 20:1997;171-178.
94. Simmonds H. A., Fairbanks L. D., Morris G. S., Webster D. R., Harley E. H. Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism. Clin Chim Acta. 171:1988;197-210.
95. Ernst M., Zametkin A. J., Matochik J. A. Presynaptic dopaminergic deficits in Lesch-Nyhan disease. N Engl J Med. 334:1996;1568-1572.
96. Meltzer H. Y. Serum creatine phosphokinase in schizophrenia. Am J Psychiatry. 133:1976;192-197.
97. Mannor I., Hermesh H., Stein D. Creatine kinase in adolescents at early acute psychosis. Eur Neuropsychopharm. 8:1998;S251-S252.
98. Rybakowski J. K., Lehman W. Decreased activity of erythrocyte membrane ATPases in depression and schizophrenia. Neuropsychobiology. 30:1994;11-14.
99. Waziri R., Baruah S., Hegwood T. S., Sherman A. D. Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics. Neurosci Lett. 120:1990;237-240.
100. Waziri R., Baruah S., Sherman A. D. Abnormal serine-glycine metabolism in the brains of schizophrenics. Schizophr Res. 8:1993;233-243.
101. Gattaz W. F., Gasser T., Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol Psychiatry. 20:1985;360-366.
102. Pettegrew J., Keshavan M. S., Pachalingam K. Alterations in brain high-energy phosphate and membrane metabolism in first-episode, drug-naive schizophrenics. Arch Gen Psychiatry. 48:1991;563-568.
103. 31phosphorous magnetic resonance spectroscopic imaging study. Biol Psychiatry. 38:1995;279-286.
104. 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia. Biol Psychiatry. 32:1992;26-32.
105. Kurumaji A., Toru M. An increase in [3H]CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Res. 808:1998;320-323.
106. Parsons B., Togasaki D. M., Kassir S., Przedborski S. Neuroleptics up-regulate adenosine A2a receptors in rat striatum: implications for the mechanism and the treatment of tardive dyskinesia. J Neurochem. 65:1995;2057-2064.
107. Deckert J., Nöthen M. M., Bryant S. P. Mapping of the human adenosine A2A receptor gene: relationship to potential schizophrenia loci on chromosome 22q and exclusion from the CATCH 22 region. Hum Genet. 99:1997;326-328.
108. Young C. R., Longhurst J. G., Bowers M. B. Jr, Mazure C. M. The expanding indications for clozapine. Exp Clin Psychopharmacol. 5:1997;216-234.
109. Hector R. I. The use of clozapine in the treatment of aggressive schizophrenia. Can J Psychiatry. 43:1998;466-472.
110. Spivak B., Roitman S., Vered Y. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol. 21:1998;245-250.
111. Tacconi M. T. Neuronal death: is there a role for astrocytes? Neurochem Res. 23:1998;759-765.
112. Di Iorio P., Ballerini P., Cacialgi F., Ciccareli R. Purinoceptor-mediated modulation of purine and neurotransmitter release from nervous tissue. Pharmacol Res. 37:1988;169-178.
113. Lieberman J. A., Sheitman B. B., Kinon B. J. Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 17:1997;205-229.